New CDC data shows nirsevimab, a long-acting monoclonal antibody, was highly effective in protecting infants from RSV-associated hospitalizations. RSV is the leading cause of hospitalization among infants in the U.S. For details, read the CDC news release.
The CDC recommends — which this study supports — giving the infant nirsevimab in the child's 1st year if the mother did not receive the maternal RSV vaccine during pregnancy, except for infants where <14 days have elapsed between vaccination and birth. Another dose can be given during the child's 2nd RSV season for some high-risk patients.
RSV prevention products remain our single most important tool to protect infants from RSV. For additional guidance on prescribing nirsevimab, read AAP's Nirsevimab FAQs.